NCT00534183

Metabolic Profile and Anthropometric Changes in Schizophrenia

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 2,006 (actual)
• Sponsor: Central Institute of Psychiatry, Ranchi, India · Academic / Other
• Sex: All
• Age: 18 Years – 40 Years
• Healthy volunteers: Not accepted

Summary

"No clinical differences will be found between the three antipsychotics under study - olanzapine, risperidone and haloperidol - on the patients' metabolic profile and weight. "

Detailed description

we aimed to study the effects of antipsychotics, olanzapine, risperidone and haloperidol on development of metabolic syndrome in a drug naïve population suffering from first episode schizophrenia and compared it with a matched healthy control group. We also aimed to examine the prevalence of metabolic syndrome as defined by the two most widely accepted definitions, the ATP IIIA and the IDF.

Conditions

• Metabolic Syndrome
• Diabetes
• Obesity

Interventions

Type	Name	Description
DRUG	Olanzapine	Olanzapine in dose range of 10-20mg
DRUG	Risperidone	Risperidone 1-6mg
DRUG	Haloperidol	Haloperidol 10-20mg

Timeline

• Start date: 2006-06-01
• Completion: 2006-12-01
• First posted: 2007-09-24
• Last updated: 2007-09-24

Locations

1 site across 1 country: India